

INTERNATIONAL SEARCH REPORT

IB2004/001390

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/00 C07K16/06 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, PAJ**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 01/77181 A (GLACET ARNAUD ;BELIARD ROLAND (FR); BOUREL DOMINIQUE (FR); FRACTIO) 18 October 2001 (2001-10-18) cited in the application page 13, lines 9-12 page 13, line 17 - page 14, line 28 page 15, line 22 - page 16, line 7 page 18, line 20 - page 20, line 3 page 21, line 24 - page 22, line 25 page 23, lines 3-8 page 32, line 23 - page 34, line 5 table 3 example 3</p> <p>-----</p> <p style="text-align: center;">-/-</p>	8-12, 20-25, 36-42

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 September 2004	30/09/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer COVONE-VAN HEES, M

INTERNATIONAL SEARCH REPORT

/IB2004/001390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SHIELDS R L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc_{gamma}RIII and antibody-dependent cellular toxicity" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733-26740, XP002964542 ISSN: 0021-9258 cited in the application abstract page 2673, right-hand column, paragraph 4</p> <p>-----</p>	1,2,4,7
A	<p>WRIGHT A ET AL: "Effect of glycosylation on antibody function: implications for genetic engineering" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 1, 1997, pages 26-32, XP004016809 ISSN: 0167-7799 page 27, left-hand column, paragraph 4 page 30, left-hand column, paragraph 4 - right-hand column, paragraph 5</p> <p>-----</p>	1-47
X	<p>WO 99/58572 A (ARMOUR KATHRYN LESLEY ; UNIV CAMBRIDGE TECH (GB); WILLIAMSON LORNA MCL) 18 November 1999 (1999-11-18) examples 6,6b page 7, line 15 - page 10, line 27</p> <p>-----</p>	1,2,4,5, 7,13,14, 36,37
A	<p>EP 0 481 790 A (WELLCOME FOUND) 22 April 1992 (1992-04-22) page 4, line 49 - page 5, line 32</p> <p>-----</p>	1-47
A	<p>DAVIES J ET AL: "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity of Fc_{gamma}RIII" BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, vol. 74, no. 4, August 2001 (2001-08), pages 288-294, XP002964541 ISSN: 0006-3592 the whole document</p> <p>-----</p>	1-47
A	<p>WO 97/28267 A (GRAY GARY S ; REPLIGEN CORP (US); SILVER SANDRA (US); CARSON JERRY (US) 7 August 1997 (1997-08-07) page 8, lines 10-21</p> <p>-----</p>	1-47